MedPath

Effect of L-Carnitine on QT-Dispersion of patients with acute myocardial infarction in Rafsanjan Ali Ibn-Abitaleb Hospital: A randomized, double-blind, placebo-controlled trial

Phase 3
Completed
Conditions
Patients with acute myocardial infarction.
ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction
Registration Number
IRCT20190128042525N3
Lead Sponsor
Rafsanjan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
200
Inclusion Criteria

Patients with Acute Myocardial Infarction with History, Examination, ECG and Cardiac Enzymes and Angiography
Patients undergoing angiography have more than 80% coronary stenosis
The type and extent of MI and age restriction are not relevant in this study.

Exclusion Criteria

Moderate and severe valvular disease
Pregnancy
Left and right bundle branch block
Patients taking vitamin supplements
Patients taking QT prolonging drugs (amiodarone, sotalol, quinidine, azithromycin, clarithromycin, erythromycin)
Underlying diseases such as diabetes (due to the effect of diabetes-induced oxidative stress on the antioxidant effects of L-carnitine) and liver failure (due to hepatic drug metabolism), and chronic renal failure grade 4 and 5 (GFR <30 mL / min / 1.73)

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
In the study Effect of oral L-carnitine tablets on QT-dispersion in patients with acute myocardial infarction hospitalized at Ali Ibn Abi Talib Hospital in Rafsanjan the primary outcome could be reduced QT-dispersion. Timepoint: In the study Effect of oral L-carnitine tablets on QT-dispersion in patients with acute myocardial infarction hospitalized in Hazrat Ali Ibn Abi Talib Hospital in Rafsanjan is the timing of measurement of QT-dispersion in the first day of study and last day. Method of measurement: The Method of measurement: how to measure the outcome variable: QT-dispersion is calculated by measuring the difference between the largest and the smallest QT. Interval in 12-lead of Electrocardiogram.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath